



Atty. Docket No. 01379/1/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF)

TIMOTHY MAZIASZ)

SERIAL NO.: 10/769,485)

FILED: January 30, 2004)

GROUP ART UNIT: 1614

EXAMINER: TBA

DATE: June 6, 2005

TITLE: METHODS AND COMPOSITIONS FOR THE TREATMENT OR
PREVENTION OF HUMAN IMMUNODEFICIENCY VIRUS AND RELATED
CONDITIONS USING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND
ANTIVIRAL AGENTS

The Commissioner of Patents
Alexandria, VA 22313

Sir:

INFORMATION DISCLOSURE STATEMENT


In accordance with 37 C.F.R. 1.97 and 1.98 MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith the attached Form PTO 1449. Applicants respectfully request that the Examiner consider and enter all the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

If any fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,

James M. Warner, Reg. No. 45,199
Attorney for Applicants
(314) 274-3642

Pharmacia Corporation
Corporate Patent Department
P.O. Box 1027
St. Louis, Missouri 63006
Customer No. 26648



Sheet 1 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 01379/1/US	APPLICATION NO.: 10/769,485
	INVENTOR: Timothy Maziasz	
	Filed: June 6, 2005	Group: 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	5	3	8	0	7	3	8	01/10/95	Norman, et al.			
	A2	5	3	4	4	9	9	1	09/06/94	Reitz, et al.			
	A3	5	3	9	3	7	9	0	02/28/95	Reitz, et al.			
	A4	5	4	3	4	1	7	8	07/18/95	Talley, et al.			
	A5	5	4	7	4	9	9	5	12/12/95	Ducharme, et al.			
	A6	5	5	1	0	3	6	8	04/23/96	Lau, et al.			
	A7	5	6	3	3	2	7	2	05/27/97	Talley, et al.			
	A8	5	5	2	1	2	0	7	05/28/96	Graneto			
	A9	5	9	3	2	5	9	8	08/03/99	Talley, et al.			
	A10	5	4	6	6	8	2	3	11/14/95	Talley, et al.			
	A11	6	0	3	4	2	5	6	03/07/00	Carter, et al.			
	A12	6	0	7	7	8	5	0	06/20/00	Carter, et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number								Date	Country	Class	Subclass	Translation	
													Yes	No
	B1	WO	96	2	5	4	0	5	22.08.96	PCT				
	B2	WO	95	1	5	3	1	6	08.06.95	PCT				
	B3	WO	94	1	5	9	3	2	21.07.94	PCT				
	B4	WO	94	2	7	9	8	0	08.12.94	PCT				
	B5	WO	95	0	0	5	0	1	05.01.95	PCT				
	B6	WO	94	1	3	6	3	5	23.06.94	PCT				
	B7	WO	94	2	0	4	8	0	15.09.94	PCT				
	B8	WO	94	2	6	7	3	1	24.11.94	PCT				
	B9	WO	98	0	3	4	8	4	29.01.98	PCT				
	B10	WO	00	2	4	7	1	9	04.05.00	PCT				
	B11	WO	02	0	6	2	1	3	24.01.02	PCT				
	B12	WO	92	1	6	1	9	2	01.10.92	PCT				
	B13	WO	91	0	8	7	6	0	27.06.91	PCT				
	B14	WO	02	0	7	7	2	1	31.01.02	PCT				
	B15	WO	96	0	6	8	4	0	07.03.96	PCT				
	B16	WO	96	0	3	3	8	7	08.02.96	PCT				
	B17	WO	96	0	3	3	8	8	08.02.96	PCT				
	B18	WO	96	1	9	4	6	9	27.06.96	PCT				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 01379/1/US	APPLICATION NO.: 10/769,485
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	INVENTOR: Timothy Maziasz	
	Filed: June 6, 2005	Group: 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	C1	J.S. James, Aspirin and AIDS, AIDS Treatment News, Issue #109 (Aug. 17, 1990), pg. 1-11
	C2	J. Hardman, et al., Goodman & Gilman's Pharm. Basis of Thera., 9 th Ed., Appendix II "Design and Optimization of Dosage Regimens – Benet, et al." (1996), pg. 1707-1711
	C3	J. Hardman, et al., Goodman & Gilman's Pharm. Basis of Thera., 10 th Ed., Appendix II "Design and Optimization of Dosage Regimens – D. Shen" (2002), pg. 475-493
	C4	S. P. Newman, Aerosols and the Lung, (1984), pg. 197-224
	C5	Kakuda, et al., Antimicrobial Agents and Chemo, (January 2001), Vol. 45, No. 1, pg. 236-242
	C6	Noormohamed, et al., Antimicrob. Agents Chemo., (1995), 39:2792-2797
	C7	Division of AIDS, NIH, Division of AIDS table, (1996)
	C8	Uberla, et al., Proc. Natl. Acad. Sci USA, Vol. 92, (August 1995), pg. 8210-8214
	C9	Lundgren, et al., J. Acquired Immune Defic. Syndr., (1991), 4:489-498
	C10	Thorstensson, et al. J. Acquired Immune Defic. Syndr., (1991), 4:374-379

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

IPW

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)			Docket No.	
Applicant(s): Timothy Maziasz			01379/1/US	
Application No. 10/769,485	Filing Date 01/30/2004	Examiner TBA	Customer No. 26648	Group Art Unit 1614
Invention: Methods and Compositions for the Treatment or Prevention of Human Immunodeficiency Virus and Related Conditions Using Cyclooxygenase-2 Selective Inhibitors and Antiviral Agents				
<div></div> <p>Hereby certify that this <u>IDS Pet, Form PTO-1449 (2pgs), Transmittal Form, Return Receipt Postcard</u> (Identify type of correspondence)</p> <p>is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on <u>June 6, 2005</u> (Date)</p> <p><u>Angela D. Smith</u> (Typed or Printed Name of Person Mailing Correspondence)</p> <p><u>Angela D. Smith</u> (Signature of Person Mailing Correspondence)</p> <p>Note: Each paper must have its own certificate of mailing.</p> <div></div>				



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/769,485	
	Filing Date	January 30, 2004	
	First Named Inventor	Timothy Maziasz	
	Art Unit	1614	
	Examiner Name	TBA	
Total Number of Pages in This Submission		Attorney Docket Number	01379/1/US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Form PTO-1449 28 References Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	James M. Warner, Reg. No. 45,199
Signature	
Date	June 6, 2005

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the			
Typed or printed name	Angela D. Smith		
Signature		Date	June 6, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.